Biocept said recently it has entered into a deal with Quest Diagnostics Mexico to expand the reach of its epidermal growth factor receptor (EGRF) mutation detecting liquid biopsy test to lung cancer patients in Mexico.
"We are pleased to collaborate with Quest Diagnostics Mexico to make our test more accessible to the many patients in Mexico with lung cancer," Biocept Vice President of Commercial Cperations Raaj Trivedi said. "This collaboration also furthers our objective of actively expanding into geographies outside the U.S. and follows our recently announced distribution agreement for Israel."
Biocept's liquid biopsy tests for cancer profiling and monitoring uses Target Selector technology that captures and analyzes circulating tumor DNA in circulating tumor cells and plasma. This helps identify cancer mutations, which in this case are EGFR mutations associated with lung cancer.
"Our high sensitivity test uses a simple blood sample to provide a cost-effective, viable option for patients with lung cancer who are often too sick for invasive tissue sampling," Trivedi said. "Detecting the EGFR mutation can qualify patients for targeted therapy treatments that could lead to better outcomes."